|
|
|
|
|
|
| MARKET RESEARCH SECTOR IN FOCUS | |
|
|
|
|
|
|
| SEARCH RESULTS |
|
Search Criteria:
Title: antibod
Published Date Range : Any Date
| Page: 1 | 2 Next Last |
Found total 40 records. |
|
|
| Title |
Published  |
Price |
| Monoclonal Antibody Markets in China |
May, 2013 |
$ 4,000.00
$ 2,000.00
|
|
| Antibody Partnering Terms and Agreements |
May, 2013 |
$ 2,995.00
|
|
| Cancer Monoclonal Antibody Partnering Terms and Agreements |
May, 2013 |
$ 1,995.00
|
|
| Competitor Analysis: Antibody-Drug Conjugates (ADC) |
Apr, 2013 |
$ 770.16
|
|
| Antibody Technologies and Attrition Rates – an industry analysis 2013 |
Mar, 2013 |
$ 2,759.74
|
|
| Next-Generation Antibody Therapeutics Market 2013-2023 |
Feb, 2013 |
£ 1,699.00
|
|
| Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion |
Jan, 2013 |
$ 3,500.00
|
|
| Fusion Antibodies Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile |
Jan, 2013 |
$ 250.00
|
|
| 4-Antibody AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile |
Jan, 2013 |
$ 250.00
|
|
| Antibody Partnering Yearbook 2013 |
Jan, 2013 |
$ 1,495.00
|
|
| Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies |
Dec, 2012 |
$ 1,283.60
|
|
| Competitor Analysis: EGF-R Antibodies – Biosimilars and Biosuperiors |
Dec, 2012 |
$ 256.72
|
|
| Global Monoclonal Antibodies Market 2011-2015 |
Nov, 2012 |
$ 1,500.00
|
|
| Competitor Analysis: Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors |
Nov, 2012 |
$ 385.08
|
|
| Competitor Analysis: TNF Antibodies – Biosimilars and Biosuperiors |
Nov, 2012 |
$ 513.44
|
|
| Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors |
Nov, 2012 |
$ 385.08
|
|
| Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors |
Oct, 2012 |
$ 385.08
|
|
| 4-Antibody AG - Product Pipeline Review - 2012 |
Jul, 2012 |
$ 500.00
|
|
| Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline |
Jul, 2012 |
$ 3,500.00
|
|
| Research Report on Chinese Monoclonal Antibody Industry, 2012 |
Mar, 2012 |
$ 3,000.00
|
|
| Cancer Monoclonal Antibodies Market to 2015 |
Mar, 2012 |
$ 1,455.00
|
|
| Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017 |
Feb, 2012 |
$ 3,500.00
|
|
| Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 |
Jan, 2012 |
$ 1,000.00
|
|
| Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market |
Dec, 2011 |
$ 3,500.00
|
|
| Next-Generation Antibody Therapies: Pipeline and Market 2011-2021 |
Nov, 2011 |
£ 1,699.00
|
|
| Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical |
Oct, 2011 |
$ 1,200.00
|
|
| Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011 |
Oct, 2011 |
$ 2,384.00
|
|
| Therapeutic Monoclonal Antibodies: World Market 2011-2021 |
Sep, 2011 |
£ 1,699.00
|
|
| Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market |
Sep, 2011 |
$ 3,500.00
|
|
| Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis |
Sep, 2011 |
$ 2,503.02
|
|
Go To Advance Search
|
|
|
|
0 items in cart
